Press Release |
23 April 2013 |
Avacta Group plc
("Avacta" or "the Group")
Appointment of Nominated Advisor and Broker
Avacta Group plc (AIM:AVCT), a global provider of innovative diagnostic tools, consumables and reagents aimed at reducing the cost of human and animal healthcare, is pleased to announce that Numis Securities Limited has been appointed as the Company's nominated adviser and broker with immediate effect.
- Ends -
For further information please contact:
Avacta Group plc Alastair Smith, Chief Executive Officer Tim Sykes, Finance Director |
Tel: +44 (0) 844 414 0452 www.avacta.com |
Nominated Advisor and Broker Numis Securities Michael Meade / Freddie Barnfield - Nominated Adviser James Black - Corporate Broking |
Tel: +44 (0) 207 260 1000 |
Media Enquiries Abchurch Communications Sarah Hollins / Adam Michael / Harriet Rae |
Tel: +44 (0) 207 398 7718 |
Notes to Editors:
Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics.
Avacta's products address one of the most significant global challenges facing mankind today - the rapidly rising cost of healthcare for a growing and ageing population.
The cost of healthcare is driven by many factors. New drugs are expensive to develop, most don't reach the patient and those that do are often very costly to prescribe. Inadequate, incorrect or slow diagnosis causes delays that lead to longer or less effective courses of treatment resulting in lengthy or repeated hospitalisation.
Avacta is dedicated to developing and providing innovative and practical tools to help drug developers get their products to market quicker and more reliably, and to providing clinicians with rapid and powerful diagnostics to improve patient treatment, helping to reduce the cost of healthcare worldwide.
Avacta joined AIM in August 2006 and is based in Wetherby, England.
For further information visit www.avacta.com